Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
Lithium leads to higher efficacy: response (categorical) YMRS/MRS decrease by ≥ 50% at end… compared with placebo (high certainty).
1 finding from 1 review
Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS… compared with valproate (moderate certainty).
1 finding from 1 review
Acceptability: total withdrawals · acute mania
Lithium showed no clear difference in acceptability: total withdrawals compared with valproate (high certainty).
1 finding from 1 review
Adverse event: tremor · acute mania
Lithium leads to higher adverse event: tremor compared with valproate (high certainty).
1 finding from 1 review
Somnolence · acute mania
Lithium leads to lower adverse event: somnolence compared with valproate (high certainty).
1 finding from 1 review
Nausea · acute mania
Lithium showed no clear difference in adverse event: nausea compared with valproate (moderate certainty).
1 finding from 1 review
Efficacy: response (categorical) YMRS/SADS‐C decrease ≥ 50% by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania
1 finding from 1 review
Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Acceptability: total withdrawals · acute mania
It is very uncertain whether lithium changes acceptability: total withdrawals compared with lamotrigine (very low certainty).
1 finding from 1 review
Adverse event: tremor · acute mania
Lithium showed no clear difference in adverse event: tremor compared with lamotrigine (moderate certainty).
1 finding from 1 review
Efficacy: response (continuous) Change in YMRS (ITT‐LOCF) from baseline to end of study · acute mania
1 finding from 1 review
Somnolence · acute mania
Lithium showed no clear difference in adverse event: somnolence compared with lamotrigine (moderate certainty).
1 finding from 1 review
Efficacy: response (categorical) YMRS/SADS‐C decrease ≥ 50% by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) YMRS/BPRS change from baseline to end of study · acute mania
1 finding from 1 review
Efficacy: response (continuous) CGI change from baseline to end of study · acute mania
1 finding from 1 review
Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Acceptability: total withdrawals · acute mania
Lithium showed no clear difference in acceptability: total withdrawals compared with carbamazepine (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · acute mania
Lithium showed no clear difference in adverse event: sedation compared with carbamazepine (low certainty).
1 finding from 1 review
Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania
It is very uncertain whether lithium changes efficacy: response (categorical) YMRS decrease by ≥ 50% by end of… compared with quetiapine (very low certainty).
1 finding from 1 review